20th St.Gallen International Breast Cancer Conference 2027
Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus
17 – 20 March 2027, Vienna / Austria
20th St.Gallen International
Breast Cancer Conference 2027
Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus
17 – 20 March 2027, Vienna / Austria
Detailed Scientific Programme 2027
The overarching title of the 20th St.Gallen International Breast Cancer Conference is “Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus”.
The conflict of interest information of our faculty will be published here closer to the conference date.
Wednesday, 17 March 2027
08:00-09:30 | Breast conserving surgery/Oncoplastic
Chairs: Carmen Leser/Walter Weber
Oncoplastic breast surgery to reduce mastectomy rates
Oncoplastic techniques: chances/limitations
Videos Oncoplastic
Panel discussion
09:30-10:00 Short Break
10:00-11:30 | Mastectomy & reconstruction
Chairs: Daphne Gschwantler-Kaulich/Florian Fitzal
E-NSM/R-NSM/C-NSM: what to prefer?
Implant-based breast reconstruction: pre- or retropectoral, mesh/ADM/nothing?
Planned PMRT and immediate reconstruction: Expander/Implant/autologous
Panel discussion
The invited faculty will be published in a few days.
Details of the industry sponsored sessions will be published in January 2027.
Chairs: Hal Burstein / Sibylle Loibl / Walter Weber
Welcome to Vienna and on behalf of the ABCSG
Michael Gnant (Austria)
Welcome on behalf of SONK, SCI and ETOP IBCSG
Beat Thürlimann (Switzerland)
20th SGBCC – Perspective from European Society of Medical Oncology (ESMO)
Giuseppe Curigliano (Italy)
20th SGBCC – Perspective from the American Society of Clinical Oncology (ASCO)
Elisabeth Mittendorf (United States)
20th SGBCC – Perspective from Chinese Society of Clinical Oncology (CSCO)
Zefei Jiang (China)
Introduction of the Hansjoerg Senn Memorial Lecture
Walter Weber (Switzerland)
The Hansjoerg Senn Memorial Lecture 2027 “Reimagining subtypes and rethinking endpoints: Can we accelerate progress?”
Eric Winer (United States)
Chairs: Giuseppe Curigliano / Elisabeth Mittendorf / Zefei Jiang
Progress and needs at the intersection of women, power, and cancer
Ophira Ginsburg (Canada)
The global role of inflammation, immunity, and obesity
Erwei Song (China)
Delivering multidisciplinary care for early breast cancer: global perspectives
Charlotte Coles (United Kingdom)
Global trials for early breast cancer: are results universal?
David Cameron (United Kingdom)
Discussion
Chairs: Beat Thürlimann / Yongmei Yin / Mafalda Oliveira
The role of neoadjuvant systemic treatments in locally-advanced ER+/HER2- breast cancer
Hope Rugo (United States)
Exceptional responders after neoadjuvant therapy in LABC: conservative/radical/no local therapy?
Maria João Cardoso (Portugal)
The positive residual node after neoadjvuant PST – what to do?
Stephanie Wong (Canada)
Special Considerations in multidisciplinary management of Inflammatory Breast Cancer (IBC)
Miriam Mutebi (Kenya)
The timing and role of breast surgery and treatment of metastatic sites in oligometastatic breast cancer
Ning Liao (China) – invited
Discussion
Thursday, 18 March 2027
Details of the industry sponsored sessions will be published in January 2027.
Chairs: Angela DeMichelle / Jens Huober / Nadia Harbeck
Mechanisms of response and resistance to adjuvant endocrine therapy and oral SERDs
Barbara Pistilli (France)
Endocrine sensitivity in eBC and optimal use of tamoxifen and aromatase inhibitors
Angela DeMichelle (United States)
Oral SERDs as adjuvant and neoadjuvant therapy: current status and future expectations
Sharon Giordano (United States)
Discussion
Chairs: Walter Weber / Shigehira Saji
Talk 1: Standards of SNLB+Axilla
Isabel Rubio (Spain)
Talk 2: Standards in breast conserving surgery
Jeong Eon Lee (South Korea)
Talk 3: Standard in breast reconstruction
Cicero Urban (Brazil)
Talk 4: Surgery for T3 and T4 breast cancers
Heba Gamal (Egypt)
Chairs: Ann Partridge / Heba Gamal / Javier Cortes
Epidemiology, biology, and outcomes in young women (< age 35) with breast cancer
Sherene Loi (Australia)
Current surgical standards in a young mutation carrier with breast cancer
Isabel Rubio (Spain)
Management of hereditary breast cancer (BRCA1/2/ PALB2) in young women
Andrew Tutt (United Kingdom)
Pregnancy-associated breast cancer, and treating breast cancer during pregnancy
Matteo Lambertini (Italy)
Fertility preservation in young women with early breast cancer
Christian Singer (Austria)
Discussion
Details of the industry sponsored sessions will be published in January 2027.
Chairs: Walter Weber / Philip Poortmans / Monica Morrow
For/Yes:
Orit Kaidar-Person (Israel)
Against/No:
Walter Weber (Switzerland)
Seconder For/Yes:
Anusheel Munshi (India)
Seconder Against/No:
Shigehira Saji (Japan)
Chairs: Isabel Rubio / Yen-Shen Lu / Carlos Barrios
Defining low risk tumors beyond anatomical staging in the modern era
Zsuzsana Bago-Horvath (Austria)
Setting boundaries: which tumors do not warrant chemotherapy (ER+, HER2+, TN)
Lucia Del Mastro (Italy)
Omission of SLNB outside INSEMA and other trials’ criteria
Monica Morrow (United States)
Optimizing or avoiding RT in low risk breast cancers: patients, tumors, volumes, fractions
Icro Meattini (Italy)
Endocrine approaches in low-risk, ER+ breast cancers
Catherine Kelly (Ireland)
Discussion
Chairs: Philip Poortmans / Anusheel Munshi
Talk 5: AI in modern radiotherapy planning
Orit Kaidar-Person (Israel)
Talk 6: De-escalation of breast cancer radiotherapy
David Krug (Germany)
Talk 7: Radiotherapy for locally advanced cancers
Anusheel Munshi (India)
Talk 8: Immunopriming with radiotherapy
Alex De Caluwé (Belgium)
Chairs: Meredith Regan / Carsten Denkert / Fabrice André
Beyond the first generation of prognostic assays in eBC – new tools for prediction and risk assessment
Zsuzsanna Varga (Switzerland)
ctDNA testing in eBC: technology, methodology and impact on future adjuvant trials
François Clément Bidard (France)
The digital pathologist: AI in eBC
Nicola Fusco (Italy)
Discussion
Chairs: Hope Rugo / Nicholas Turner / Marcus Vetter
Neoadjuvant immunotherapy: state of the art for eTNBC and ER+/HER2- cancers
Jens Huober (Switzerland)
Biomarkers for patient selection for immunotherapy
Laurence Buisseret (Belgium)
The challenge of residual disease: ADCs and other innovations in the post-preoperative setting
Sibylle Loibl (Germany)
Discussion
Details of the industry sponsored sessions will be published in January 2027.
Friday, 19 March 2027
Details of the industry sponsored sessions will be published in January 2027.
Chairs: Icro Meattini / Virginia Kaklamani / Zhi-Ming Shao
Molecular characterization and therapeutic implications of ILC
Cristina Saura (Spain)
Imaging advances in lobular breast cancer (Screening, Staging, etc.)
Jana de Boniface (Sweden)
What is the role of chemotherapy in ILC?
Dario Trapani (Italy)
Unique surgical and radiotherapy considerations in ILC
Marie-Jeanne Vrancken-Peeters (Netherlands)
Discussion
Chairs: Beat Thuerlimann / Soumen Das
Talk 9: Multidisciplinary therapy of LABC
Denisse Bretel Morales (Peru)
Talk 10: Adjuvant endocrine therapy in ER+HER2- eBC
Antonio Marra (Italy)
Talk 11: Adjuvant CDK4/6 inhibitor therapy – for whom?
Marcus Vetter (Switzerland)
Talk 12: Bone-targeted therapies in eBC
Mattea Reinisch (Germany)
Chairs: Anusheen Munshi / Cicero Urban / TBA
Innovations in mastectomy: robotic techniques, and nerve preservation approaches
Stewart McIntosh (United Kingdom)
Surgery to treat lymphedema
Zhi-Ming Shao (China)
Radiation therapy fractions: 25, 15, 5, or 1?
Daniela Kauer-Dorner (Austria)
Re-irradiation for local recurrence: who, when, how?
Marcin Kubeczko (Poland)
Discussion
Chairs: Giuseppe Curigliano / Beat Thürlimann / Michael Gnant
Details of the industry sponsored sessions will be published in January 2027.
Chairs: Lisa Carey / Barbara Pistilli / Erika Hamilton
For/Yes:
Rebecca Dent (Singapore)
Against/No:
Chuck Geyer (United States)
Seconder For/Yes:
Andreas Hartkopf (Germany)
Seconder Against/No:
Eriko Tokunaga (Japan)
Chairs: Bahadir Gulluoglu / Soumen Das / Eriko Tokunaga
Adjuvant or neoadjuvant use of CDK4/6 inhibitors in early breast cancer: current data
Virginia Kaklamani (United States)
Detecting recurrence early – the role of imaging, tumor markers, CTCs, and ctDNA
Nicholas Turner (United Kingdom)
“Eligibility” or absolute risk: which patients with ER+ eBC warrant newer adjvuvant therapy?
Fabrice André (France)
Can we replace adjuvant chemotherapy with adjuvant CDK4/6 inhibitors in eBC?
Nadia Harbeck (Germany)
How should menopausal status affect decisions on chemotherapy, CDK46i, and other treatments in ER+ eBC
Meredith Regan (United States)
Discussion
Chairs: Michael Gnant / Meteb Al-Foheidi
Talk 13: Neoadjuvant and adjuvant chemotherapy
Carlos Barrios (Brazil)
Talk 14: Using ADCs in eBC
Meteb Al-Foheidi (Saudi Arabia)
Talk 15: Therapy escalation and De-escalation in eTNBC
Gabriel Rinnerthaler (Austria)
Talk 16: Managing side effects of systemic therapy
TBA
Chairs: Sara Tolaney / Meteb Al-Foheidi / Jeong Eon Lee
Digital health innovations to improve the patient experience in eBC
Nicholas Zdenkowski (Australia)
Innovations in non-hormonal approaches for symptoms of estrogen deprivation and ET
Ann Partridge (United States)
Reconsidering the role of HRT in breast cancer survivors: why, who, how?
Laura Michel (Germany)
New frontiers in survivorship: Long-term effects of immunotherapy, CDK46i, and ADCs
Mafalda Oliveira (Spain)
Discussion
Chairs: Sibylle Loibl / Binghe Xu / Sherene Loi
Neoadjuvant and adjuvant utilization of ADCs in HER2+ eBC
Sara Tolaney (United States)
Can ADCs replace chemotherapy in neoadjuvant eTNBC management?
Javier Cortes (Spain)
What evidence will we need for substituting ADCs for chemotherapy in ER+ eBC
Erika Hamilton (United States)
Discussion
Details of the industry sponsored sessions will be published in January 2027.
Saturday, 20 March 2027
Moderator: Hal Burstein
Interactive Input: Michael Gnant
Part 1
Chairs: Giuseppe Curigliano / Michael Gnant / Sibylle Loibl
Introducing the panel: why St Gallen matters
The largest tumor board in the world – get ready!
St.Gallen International Consensus Session on the optimal primary treatment of breast cancer 2027 – Seeking consensus on evidence and opinions
Coffee Break at approx. 10:30
Part 2
Chairs: Giuseppe Curigliano / Walter Weber / Beat Thürlimann
St.Gallen International Consensus Session on the optimal primary treatment of breast cancer 2027 – Seeking consensus on evidence and opinions
Kindly note that the “SGBCC Academy – Meet the Expert” Sessions as well as all “Voice of” Sessions will take place in break out rooms. All other sessions will take place in the plenary hall A.
Important Dates for SGBCC 2027
Mark your calendar to not miss any of our key dates and deadlines for your attendance and abstract submission to SGBCC 2027!
Registration opens
Start Abstract submission
Registration Early Bird & Abstract Submission Deadline
Regular Registration Fee Deadline
SGBCC 2027
